Breaking Finance News

AstraZeneca PLC (LON:AZN) has been retained to Buy in a report by Deutsche Bank today.

Deutsche Bank has retained AstraZeneca PLC (LON:AZN) to Buy in a report released on 10/05/2016.

Previously on 10/4/2016, Bryan Garnier released a statement on AstraZeneca PLC (LON:AZN) bumped down the target price from 5,400.00GBX to 5,220.00GBX that suggested an upside of 0.03%.

Yesterday AstraZeneca PLC (LON:AZN) traded 1.19% higher at 5,080.00GBX. AstraZeneca PLC’s 50-day moving average is 5,005.11GBX and its 200-day average is 4,435.88GBX. With the last close up 14.80% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 3,384,720 shares of AstraZeneca PLC exchanged hands, up from an avg. volume of 2,645,380

See Chart Below

AstraZeneca PLC (LON:AZN)

With a total market value of 0 GBX, AstraZeneca PLC has one year low of 3,680.00GBX and a one year high of 5,505.00GBX with a PE ratio of 29.10 .

Also covering AstraZeneca PLC's target, a total of 29 firms have reported on AstraZeneca PLC. The 12-month price target is 61.96GBX with four equity analysts rating the company a strong buy, 14 brokerages rating the stock a buy, 13 firms rating the stock a hold, 2 brokers rating the stock a underperform, and lastly one equity analyst rating the company a sell.

General Company Details For AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.